P654. Disease impact of ulcerative colitis on patients' perception: an Italian survey
E. Calabrese1, V. Annese2, G.C. Sturniolo3, G. Venturelli4, L. Neri5, F. Pallone1, 1University of Rome Tor Vergata, GI Unit, Medicine, Rome, Italy, 2AOU Careggi, Italy, 3Università di Padova, Italy, 4Doxafarma, Italy, 5University of Milan, Italy
Few large scale studies of the impact of ulcerative colitis (UC) in a “real-life” setting are available. In this study a multidimensional evaluation of patients' life was obtained with a nation-wide survey in 19 community hospitals and 12 academic referral centers.
The survey was conducted between June and December 2011, using a standardized questionnaire administered during the hospital visits over a one month period. The patients' attitudes and perceptions, adherence to therapy, QoL (assessed by IBDQ), and access to health service was evaluated. Eligible patients (pts) consisted of men and women at least of 15 years of age with UC confirmed by standard clinical, endoscopic and histopathological criteria. Pts with previous colectomy or proctitis were excluded.
A total of 858 pts completed the survey. The majority self-reported to be in remission (51%), with a mean of 4.1 flares during the past 5 years with no differences for age and gender. A mean of 1.1 and 0.5 hospitalizations related or not to UC during the past 5 years were reported, respectively. Overall, the IBDQ scores were similar in pts with disease duration over 10 years than in pts diagnosed less than 3 years (4.97 and 5.01, respectively). The IBDQ scores were also lower in pts with active and chronically active disease than in pts with remission (4.18, 4.22 and 5.55, respectively). Only 35% of pts on combined (oral and topical) therapy reported to adhere to treatment, whereas 47% of pts reported to forget at least one pill during last 2 weeks. Twenty-eight per cent of pts reported a poor adherence to therapy, irrespective of gender, education, and employment status.
Patients generally revealed a great impact of UC on day-by-day life, including disease burden and control, quality of life, coping skills, and treatment adherence.
On behalf of: Ardizzone S. Milano, Atzei A. Cagliari, Bernasconi G. Busto Arsizio, Biancone L. Roma, Castiglione F. Napoli, Coccia G. Genova, D'Inca' R. Padova, Costa F. Pisa, Danese S. Milano, Daperno M. Torino, De Petris G. Trento, Di Mario F. Treviso, Di Todaro E. Taranto, Di Sabatino A. Pavia, Fries W. Messina, Gallo V. Salerno, Gionchetti P. Bologna, Hadad Y. Lecce, Kohn A. Roma, Manca A. Cuneo, Milla M. Firenze, Merli M. Roma, Neri M. Chieti, Orlando A. Palermo, Pomarico G. Andria, Salvagnini M. Vicenza, Sarpi L. Perugia, Terpin M. Legnano, Tomarelli L. Ancona, Vecchi M. Milano, Zilli M. Udine.